New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
Healthcare Conference to be held in New York on June 24-25.
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
12:01 EDTCRMESteadyMed, Cardiome enter into license agreement for Treyvent rights
Subscribe for More Information
10:09 EDTONVOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:04 EDTCRMESteadyMed, Cardiome enter into license agreement for Trevyent
Subscribe for More Information
06:56 EDTONVOOrganovo initiated with a Buy at Jefferies
Target $5.
05:41 EDTONVOOrganovo initiated with an Overweight at Piper Jaffray
Subscribe for More Information
June 23, 2015
10:00 EDTALROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:14 EDTBINDOn The Fly: Pre-market Movers
Subscribe for More Information
08:09 EDTSNTASynta says Hsp90 cancer treatment 'therapeutically advantageous'
Subscribe for More Information
07:31 EDTBINDBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
06:13 EDTALRAlere upgraded to Buy from Neutral at Goldman
Goldman upgraded Alere to Buy and increased its price target to $60 from $50. The firm believes management's focus on improving the cost structure and potential for improved execution is underappreciated. Goldman sees margin leverage driven by new product launches, manufacturing and sourcing initiatives, and slowing regulatory headwinds. Further, potential divestitures of non-core assets will continue to de-leverage the balance sheet.
June 22, 2015
10:16 EDTBINDBIND Therapeutics names Andrew Hirsch as president and CEO
BIND Therapeutics announced that Andrew Hirsch has been appointed president and CEO of the company. Hirsch had been serving in the role on an acting basis since March. Hirsch has also been elected to BIND’s Board of Directors. “After a thorough evaluation of internal and external candidates, the Board is confident that Andrew is the right person to lead the next phase of the company’s growth,” said Daniel Lynch, Chairman, BIND Therapeutics Board of Directors.
June 18, 2015
09:10 EDTCRMECardiome management to meet with Brean Capital
Subscribe for More Information
09:04 EDTONVOOn The Fly: Pre-market Movers
Subscribe for More Information
08:59 EDTONVOOrganovo 9.425M share Spot Secondary priced at $4.25
Subscribe for More Information
June 17, 2015
16:04 EDTONVOOrganovo files to sell common stock, no amount given
Subscribe for More Information
10:19 EDTONVOHigh option volume stocks
Subscribe for More Information
09:03 EDTAVNRAvanir's AVP-825 device for migraine shows positive results
Avanir's COMPASS Phase IIIb, cross-over clinical trial comparing the efficacy and safety of AVP-825 22mg to sumatriptan 100mg tablets for the treatment of acute migraine across multiple attacks, showed that patients treated with AVP-825 achieved pain relief and pain freedom in significantly more migraine attacks at all time points from 15-90 minutes post-dose compared to sumatriptan tablets. A New Drug Application for AVP-825 has been accepted and is currently under review by the FDA with a Prescription Drug User Fee Act goal date of November 6.
June 16, 2015
09:04 EDTGALEGalena data encouraging, says Roth Capital
After Galena announced data from a Phase II study of its GALE-401 drug, Roth Capital says the data is encouraging and reduces the drug's clinical risk. The firm calls the drug promising and keeps an $8 price target and Buy rating on the shares.
June 15, 2015
07:19 EDTGALEGalena presents GALE-401 Phase 2 data at EHA
Galena Biopharma announced that data from the company's Phase 2 clinical trial of GALE-401 was presented at the European Hematology Association, or EHA, 20th Congress in Vienna, Austria. The GALE-401 Phase 2 pilot study is a single arm, open label, multi-center study evaluating the efficacy and safety of anagrelide controlled release in subjects with thrombocytosis secondary to essential thrombocythemia, or ET, and other myeloproliferative neoplasms, or MPNs. The poster presentation, entitled, "Phase 2 Study of a Novel Controlled-Release Formulation of Anagrelide, or GALE-401, in Subjects with Myeloproliferative Neoplasm, or MPN,-Related Thrombocytosis," was presented on Saturday, June 13, 2015. The Phase 2 study demonstrated that GALE-401 was well tolerated with primarily Grade 1 and 2 toxicities in 16 of the 18 subjects enrolled. The efficacy shown in the trial compares favorably to historical anagrelide immediate release, or IR, response rates with the following platelet response: overall response rate, or ORR, of 78%; complete response, or CR, of 39%; partial response of 39%. The median time to response was 5 weeks, and the median duration of response has not yet been reached. Based on the data, the investigators concluded that GALE-401 remains a viable potential treatment option for MPNs, and a randomized trial comparing GALE-401 versus anagrelide IR is warranted. Final data from the GALE-401 Phase 2 trial is expected to be presented at the American Society of Hematology conference in December.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use